CSL (ASX:CSL) — Material Events
ASX:CSL · 10 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
CSL Commits US$355 Million to Rare Kidney and Liver Drug PartnershipHigh
CSL pays US$355 million upfront to secure rare kidney and liver disease drug partnership
5 Oct 2026
·Strategic Partnership and Licensing Agreement
·Unexpected
·92
CSL appoints ViiV chief Deborah Waterhouse as CEO from February 2027High
CSL appoints ViiV Healthcare CEO Deborah Waterhouse to lead company from February 2027
21 Oct 2026
·Executive Appointment
·92
CSL Cuts FY26 Revenue Forecast, Flags $5 Billion Asset ImpairmentsHigh
CSL revises FY26 guidance down, announces $5 billion impairments, leadership changes
11 May 2026
·Interim CEO Review and Financial Update
·Unexpected
·85
CSL Reports US$15.8 Billion Revenue but Statutory Loss of US$2.6 Billion Amid Major RestructuringHigh
CSL reports FY26 revenue growth, large impairments, and outlines FY27 growth outlook with transformation progress
18 Aug 2026
·Full Year Results Presentation
·Unexpected
·85
CSL’s $1.9b NPATA Dip Masks Ambitious Growth and $750m Buy-Back BoostHigh
CSL reports 7% underlying NPATA decline, maintains FY26 guidance amid transformation and $750m buy-back
11 Feb 2026
·Half Year Financial Report
·85
CSL Reports $8.3B Revenue, Advances Transformation, Maintains FY26 OutlookMedium
CSL Limited reports 1H26 results with $8.3B revenue, strong transformation progress, maintains FY26 guidance, expands share buyback
11 Feb 2026
·Results Presentation
·85
CSL’s Profit Plummets 80% Amid $2 Billion Restructuring and ImpairmentsHigh
CSL reports 80% profit drop due to $2.06B impairments, maintains growth guidance and dividends
11 Feb 2026
·Results Announcement
·Unexpected
·85
CSL faces class action over alleged FY26 disclosure failuresHigh
CSL faces Victorian class action over alleged disclosure breaches and FY26 performance statements
22 Oct 2026
·Class Action Notification
·Unexpected
·78
CSL CEO Paul McKenzie Retires; Gordon Naylor Steps In as Interim LeaderMedium
CSL CEO Paul McKenzie retires; Gordon Naylor named interim CEO
10 Feb 2026
·Executive Leadership Change
·75
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where CSL (ASX:CSL) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026
24 Oct 2026
Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026
24 Oct 2026
Market Wrap - Week 41 (5 Oct -> 9 Oct) 2026
10 Oct 2026
Market Wrap - Week 34 (17 Aug -> 21 Aug) 2026
22 Aug 2026
Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026
22 Aug 2026